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Financing  for  global  health  is a  critical  element  of  research  and  development.  Innovations  in  new  vac-
cines are  critically  dependent  on  research  funding  given  the  large  sums  required,  however  estimates  of
global  research  investments  are  lacking.  We  evaluate  infectious  disease  research  investments,  focusing
on immunology  and  vaccine  research  by  UK  research  funding  organisations.  In  1997–2010,  £2.6 billion
were  spent  by public  and  philanthropic  organisations,  with  £590  million  allocated  to immunology  and
vaccine  research.  Preclinical  studies  received  the  largest  funding  amount  £505  million  accounting  foreywords:
accine
mmunology
nfectious disease
ublic health policy
85.6%  of total  investment.  In terms  of  speciﬁc  infection,  “the  big  three”  infections  dominated  funding:
HIV  received  £127  million  (21.5%  of  total),  malaria  received  £59  million  (10.0%  of  total)  and  tuberculosis
received  £36  million  (6.0%  of  total).  We  excluded  industry  funding  from  our analysis,  as  open-access  data
were unavailable.  A  global  investment  surveillance  system  is needed  to  map  and  monitor  funding  and
 resoesearch investments
esearch and development
guide  allocation  of  scarce
. Introduction
Vaccines are the most cost-effective health intervention for
he prevention of disease [1]. Since their invention, vaccines have
een administered to billions of individuals with signiﬁcant health
nd economic beneﬁts, particularly to people in low- and middle-
ncome countries [2,3].
Public funders, philanthropic institutions, pharmaceutical com-
anies and biotech companies all play a role in the research and
evelopment (R&D) of new vaccines. A WHO–UNICEF analysis esti-
ated that US$76 billion was required for immunisation strategies
or 2006 to 2015 among 117 low- and middle-income countries
lone [4]. Although, since 2000, international ﬁnancing of global
ealth has increased substantially [5]; the Global Immunisation
ision and Strategy for 2006–2015 is under funded by US$11–15
illion [6,7].
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Since 2007, R&D expenditures have been estimated for global
neglected diseases [8]. A recent study, which reviewed 6170 studies
accounting for £2.6 billion of investments, documented for the ﬁrst
time in detail research investments for infectious diseases in the
UK or for the UK institutions and the global partners involved in
infectious disease research [9]. However, annual expenditures on
vaccine research have not been estimated [10]. The United Kingdom
(UK) is the second largest investor in global health; however, there
are no analyses of R&D funding allocated to vaccine research and
delivery. Investments by the UK pharmaceutical industry are also
poorly documented, primarily due to commercial sensitivity of the
data on R&D funding.
In this study, we systematically analyse the ﬁnancing for vaccine
research and immunology of infectious diseases.
2. Methods
We  systematically searched databases and websites for infor-
mation on research investments for the period 1997–2010. We
identiﬁed 325,922 studies for screening and included 6165 stud-
ies in the ﬁnal analysis (supplementary ﬁgure 1). We  created a
comprehensive database of open-access infectious disease research
projects and categories studies and funding by disease, cross-
cutting research theme, and categories along the R&D value chain
[9]. The R&D categories included: pre-clinical research; phase 1, 2
or 3 trials; product development; and implementation research.
reserved.
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Fig. 1. Bar graph showing: A) total investment in immunology and vaccine research
opment was the least well-funded type of immunology and vaccine
research with £12.5 million (2.1%).J.R. Fitchett et al. / Vac
reclinical research refers to all basic science studies. Clinical
rials included phase 1, phase 2 and phase 3 studies. Prod-
ct development research included new product trials, phase 4
tudies and post-marketing research. Implementation research
ncludes all operational, epidemiological, social science and health
conomics studies. A speciﬁc analysis of immunology and vac-
ine research is presented in this paper due to the signiﬁcant
elevance of host-pathogen interactions to new vaccine develop-
ent. Further information on detailed methodology is available
nline (http://researchinvestments.org/data) and published else-
here [9].
Variables collected included the study title, abstract, funding
warded to the study, lead institution, principal investigator, and
he year of award. We  included all immunology and vaccine-related
tudies for infectious diseases where the lead institution was based
n the UK. We  excluded immunology and vaccine studies not imme-
iately relevant to infectious diseases. Veterinary infectious disease
esearch was excluded unless there was a clear zoonotic com-
onent. We  excluded open-access data from the pharmaceutical
ndustry, due to paucity of publically available data. All grant fund-
ng amounts were adjusted for inﬂation and reported in 2010 UK
ounds. Grants were not modiﬁed according to levels of overheads
pplied to the award. Grants awarded in a currency other than
ounds were converted to UK pounds using the mean exchange
ate in the year of award.
A team of researchers and the authors sourced data for the study
ver 3 years (September 2007 to December 2010). Data were cat-
gorised between December 2010 and April 2012 and analysed in
wo steps: between October 2011 and May  2012, and in July 2013.
icrosoft Excel software was used for data categorisation. We  used
old differences and statistical tests (nonparametric Mann-Whitney
ank sum test, K-sample test and nonparametric Wilcoxon signed-
ank test) to compare total investment, number of studies, mean
rant, and median grant according to speciﬁc infection, disease sys-
em, funding organisation, and cross-cutting categories. Statistical
nalysis and generation of ﬁgures and graphs were performed using
tata software (v11).
Table 1
. Results
We  identiﬁed a total research investment of £590 million across
276 studies for immunology and vaccine research, accounting for
2.7% of total research investment in infectious diseases, which was
2.6 billion. Funding explicitly for vaccine research amounted to
235 million across 368 studies (9.0% of total).
Diagnostics research accounted for £100.3 million across 407
tudies (3.8%) and therapeutics accounted for £408.5 million across
26 studies (15.7%) of total funding of £2.6 billion.
Research with a clear global focus or performed with a partner
rganisation accounted for £170 million across 264 studies (28.8%
f the £590 million for immunology and vaccine research). Figure 1
hows total investment for immunology of infectious diseases and
accine research studies over time without a clear long-term pat-
ern, with peaks in funding in the years 2000, 2005, 2006 and 2008.
Figure 2 shows total investment for immunology of infectious
iseases and vaccine research studies by speciﬁc infection. HIV
esearch received the most investment for immunological research
ith £126.6 million (21.5% of total), followed by malaria with £58.8
illion (10.0%) and tuberculosis (TB) with £35.6 million (6.0%).
nly 16 out of 45 major infectious diseases (35.6%) included in
his analysis received over £1 million funding over the 14-year
tudy period. Pathogens attracting low investment for vaccine
esearch from public and philanthropic funders included Dengue
irus, Norovirus, Clostridium difﬁcile,  Escherichia coli,  Neisseria Gon-
rrhoea, and Staphylococci spp.over time by R&D pipeline and B) proportion of investment over time by R&D
pipeline.
According to the type of research along the R&D value chain, pre-
clinical research attracted the most investment with £505.1 million
(85.6%) followed by phase 1, 2, 3 trials with £41.2 million (7.0%) and
implementation research with £31.6 million (5.4%). Product devel-Fig. 2. Bar graph showing total investment in vaccine research by speciﬁc infection
(for infections with > £1 million research expenditure).
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Table 1
Funding for vaccine research and immunology of infectious diseases.
Infectious disease total (n = 6165) Immunology (n = 1271) Vaccine (n = 368)
£ (%) n (%) Median (IQR) £ (%) n (%) Median (IQR) £ (%) n (%) Median (IQR)
Overall funding 2,599,985,851 (100) 6165 (100) 158,055
(49,490–352,699)
590,183,505 (100) 1271 (100) 203,141
(91,772–409,829)
235,272,456 (100) 368 (100) 226,680
(98,843–589,875)
Preclinical 1,622,545,777 (62.4) 4037 (65.5) 193,149
(74,157–365,587)
505,113,878 (85.6) 1121 (88.2) 202,198
(94,676–396,881)
159,921,393 (68.0) 246 (66.8) 239,727
(107,786–570,651)
Phase  1, 2, 3 146,827,393 (5.6) 145 (2.4) 213,471
(53,116–839,713)
41,039,362 (7.0) 62 (4.9) 269,145
(116,470–1,036,952)
38,113,582 (16.2) 62 (16.8) 250,021
(106,796–774,912)
Product development 132,878,829 (5.1) 335 (5.4) 147,621
(38,625–409,663)
12,475,422 (2.1) 24 (1.9) 196,876
(75,941–706,801)
10,460,905 (4.4) 18 (4.9) 223,741
(68,457–825,550)
Operational research 697,733,852 (26.8) 1648 (26.7) 88,232
(18,513–250,423)
31,554,844 (5.3) 64 (5.0) 151,297
(33,694–394,057)
26,776,576 (11.4) 42 (11.4) 202,911
(62,976–452,939)
Microbiology 2,331,026,142 (90.0) 5380 (87.3) 169,740
(52,373–359,391)
503,038,338 (100) 1044 (100) 221,468
(90,564–458,654)
198,337,432 (100) 321 (100) 221,730
(94,470–578,651)
Bacteriology 588,296,526 (22.6) 1995 (32.4) 162,281
(43,788–306,974)
106,739,486 (21.2) 328 (31.4) 194,633
(83,956–333,141)
52,329,638 (26.4) 135 (42.1) 186,341
(86,947–351,372)
Virology 1,027,385,668 (39.5) 2147 (34.8) 160,555
(49,400–371,794)
277,200,289 (55.1) 491 (47.0) 229,851
(103,768–566,629)
108,946,914 (54.9) 142 (44.2) 294,610
(93,936–590,504)
Parasitology 666,939,464 (25.7) 1067 (17.3) 216,260
(70,194–461,390)
118,172,134 (23.5) 220 (21.1) 258,990
(96,401–555,787)
37,060,881 (18.7) 44 (13.7) 346122
(160,298–1,270,540)
Mycology 48,404,484 (1.9) 171 (2.8) 138,258
(41,162–338,222)
926,429 (0.2) 5 (0.5) 45,528
(34,229–296,635)
0 0 -
Public  funding 1,403,579,619 (54.0) 2385 (38.7) 255,992
(127,167–529,610)
293,970,066 (49.8) 471 (37.1) 319,694
(178,939–669,138)
129,225,930 (54.9) 170 (46.2) 361,232
(178,182–760,160)
BBSRCa 186,268,429 (7.2) 578 (9.4) 253,398
(169,787–365,159)
46,325,975 (7.8) 153 (12.0) 256,661
(123,344–355,566)
16,031,780 (6.8) 55 (14.9) 274,839
(109,210–396,881)
UK  Government 154,438,214 (5.9) 341 (5.5) 110,178
(19,073–206,784)
4,409,838 (0.7) 32 (2.5) 126,387
(19,119–206,784)
1,690,882 (0.7) 12 (3.3) 126,387
(20,461–187,943)
Department of Health 134961745 (5.2) 285 (4.6) 203,544
(72,628–514,066)
9,333,940 (1.6) 20 (1.6) 210,809
(115,619–458,833)
9,050,409 (3.8) 18 (4.9) 229,557
(93,936–523,608)
MRCb 672,895,698 (25.9) 962 (15.6) 366,479
(199,287–713,178)
171,420,403 (29.0) 227 (17.9) 465,698
(233,658–878,307)
59,773,451 (25.4) 64 (17.4) 590,489
(311,465–1,039,362)
European Commission 255,015,533 (9.8) 219 (3.6) 439762
(127,419–1,454,941)
62,479,910 (10.6) 39 (3.1) 1,040,540
(159–841–1,679,813)
42,679,408 (18.1) 21 (5.7) 1,281,261
(844,207–2,463,962)
Philanthropic funding 1,102,469,932 (42.4) 2874 (46.6) 146,060
(52,433–286,518)
275,611,267 (46.7) 699 (55.0) 153,858
(78,748–299,148)
89,229,325 (37.9) 156 (42.4) 161,257
(69,750–325,119)
Gates  Foundation 220,923,242 (8.5) 39 (0.6) 1,488,432
(628,545–5,576,863)
34,196,740 (5.8) 10 (0.8) 1,509,077
(355,370–5,457,881)
28,738,860 (12.2) 9 (2.4) 628,545
(355,370–3,496,833)
Charity  193,459,157 (7.4) 851 (13.8) 87,318
(27,616–167,829)
37,631,965 (6.4) 200 (15.7) 114,416
(55,892–192,383)
10,427,688 (4.4) 81 (22.0) 112,012
(49,738–174,086)
IAVIc 8,893,468 (0.3) 11 (0.2) 305,339
(305,339–1,132,624)
8,893,468 (1.5) 11 (0.9) 305,339
(305,339–1,132,624)
8,893,468 (3.8) 11 (3.0) 305,339
(305,339–1,132,624)
Wellcome Trust 688,087,494 (26.5) 1984 (32.2) 168,434
(66,419–335,557)
203,782,561 (34.5) 489 (38.5) 167,066
(99,591–356,867)
50,062,778 (21.3) 66 (17.9) 244,795
(135,530–981,193)
Other  funding 85,042,871 (3.3) 895 (14.5) 28,006
(6,193–98,621)
11,708,705 (2.0) 90 (7.1) 45,790
(11,638–137,759)
7,923,733 (3.4) 31 (8.4) 94,470
(19,058–249,363)
a Biotechnology and Biological Sciences Research Council.
b Medical Research Council.
c International AIDS Vaccine Initiative.
cine 3
i
a
s
i
(
4
i
o
s
f
i
a
r
h
i
a
i
s
i
i
s
h
g
i
d
t
h
(
d
d
b
r
r
m
h
c
&
r
A
O
U
t
i
a
i
rJ.R. Fitchett et al. / Vac
Public funding accounted for £294.0 million across 471 stud-
es (49.8%) with philanthropic funding awarding £275.6 million
cross 699 studies (46.7%). The major funding organisations to
upport this work included the Wellcome Trust (34.5%), the Med-
cal Research Council (MRC; 29.0%) and the European Commission
10.6%).
. Discussion
We  present the ﬁrst detailed analysis of vaccine research fund-
ng awarded to UK institutions and their global partners. The trends
ver the period of analysis do not indicate that an obvious ﬁnancing
trategy is pursued by the funding agencies.
Immunology and vaccine research receives large amounts of
unding compared to other scientiﬁc disciplines [9]. However, this
s likely due to the high costs associated with vaccine development
nd immunological research. More work is required to estimate the
esearch shortfall for infectious diseases and the cost of inaction on
ealth outcomes.
Our study highlights clear signiﬁcant differences in the research
nvestment according to speciﬁc infectious disease. HIV, malaria
nd TB dominate the research funding landscape, with very limited
nvestment for immunology and vaccine research allocated to other
erious infections.
Preclinical research dominates the R&D funding landscape for
mmunology and vaccine research. Although an essential part of
nnovation, strategic measures to promote the translation of basic
cience into clinical practice could have signiﬁcant beneﬁts in
ealth outcomes and stimulate greater advances in new technolo-
ies to eliminate or eradicate infectious diseases.
Our data does not include contribution from the pharmaceutical
ndustry, which is especially important in vaccine research, as these
ata are not publically available.
We urge pharmaceutical companies and industry partners
o share their detail with the wider scientiﬁc community. We
ave established RESIN: Research Investments in Global Health
www.researchinvestments.org), a public good to document and
isseminate research investment data in an online open-access
atabase to beneﬁt academic institutions and pharmaceutical and
iotech companies. It is unlikely that divulging past and cur-
ent research investments would jeopardise current and future
esearch, where commercially sensitive data can be redacted and
ay  help avoid duplication of research investments in global
ealth.
We analysed major funding organisations, including the Well-
ome Trust, the MRC  and the European Commission. The Bill
 Melinda Gates Foundation is also a major funder for vaccine
esearch and delivery, particularly with donations to the GAVI
lliance for making available vaccines in low-income countries.
ur analysis is likely to underestimate global ﬁnancing, as the
nited States (US) funding agencies such as the National Insti-
utes of Health are not included. Further limitations of our study
nclude difﬁculties in ascertaining the right proportion of a grant
llocated to a speciﬁc disease category. This is particularly relevant
n co-infection studies.
It is essential that we map, monitor and evaluate vaccine
esearch funding given the importance of vaccines to global health.
[1 (2013) 5930– 5933 5933
Data on current investments, coupled with data on disease burden
and efﬁcacy of interventions, will help improve allocation of scarce
resources. We  urge funding organisations to make available ﬁnan-
cing data on their investment portfolios, as with the clinical trials
registry ClinicalTrials.gov, to inform policy on vaccine research.
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